Phenotypes Associated with This Genotype

Genotype
MGI:5779422

• Allelic Composition: Gt(ROSA)26Sor^{tm1.1(rtTA2S*M2)Whsu}/Gt(ROSA)26Sor⁺; Ncstn^tm1.1Akli/Ncstn^tm1.1Akli; Tg(tetO-cre)1Jaw/0
• Genetic Background: involves: 129 * 129S6/SvEvTac * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

increased urinary bladder carcinoma incidence ( J:227748 )

• doxycycline (dox) treated mice rapidly develop invasive urothelial cancer

• tumors of dox treated mice are high-grade urothelial carcinomas, grow mostly with a solid, non-glandular pattern and show blunt cellular atypia and focal glandular differentiation

• tumors invade the lamina and muscularis propria

• marker analysis indicates that tumors are related to human basal BLCA3 subtype

renal/urinary system

increased urinary bladder carcinoma incidence ( J:227748 )

• doxycycline (dox) treated mice rapidly develop invasive urothelial cancer

• tumors of dox treated mice are high-grade urothelial carcinomas, grow mostly with a solid, non-glandular pattern and show blunt cellular atypia and focal glandular differentiation

• tumors invade the lamina and muscularis propria

• marker analysis indicates that tumors are related to human basal BLCA3 subtype

hydronephrosis ( J:227748 )

• 12 of 18 mice develop unilateral or bilateral hydronephrosis as early as 2 weeks after dox treatment due to obstruction of the upper ureter by tumor masses

ureter obstruction ( J:227748 )

• due to bladder tumors in dox treated mice

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
urinary bladder cancer		DOID:11054	OMIM:109800	J:227748